Your go-to research tool for forward-looking insights into autoimmune and chronic inflammatory diseases.

As commercial and clinical teams plan strategies for differentiation and success, they rely on the series for up-to-date, data-driven insights, across 20 immunology indications.

Have confidence that you understand the implications of the changing landscape in the immunology space and you are equipped with the knowledge to inform clinical investment decisions.

 

With the SMARTImmunology insights, you will:

  • Acquire comprehensive foundational data and forward-looking perspective on various indications in the immunology space
  • Stay up-to-date with updates after key conferences (e.g., ACR and EULAR)
  • Get a global perspective, based on ongoing monitoring of scientific progress in the area and capture implications on the future thresholds for differentiation for new market entrants
  • Consolidate key data-driven insights and data in one concise report and avoid internal “fire drills” accessing data
  • Get a presentation-ready format (PowerPoint slides)
  • Quickly get up to speed on an indication when evaluating business development opportunities
Diseases Covered in the Series
Acute Graft versus Host Disease (aGvHD)
Ankylosing Spondilities
Atopic Dermatitis
Chronic Graft versus Host Disease (cGvHD)
Crohn’s Disease
Eosinophilic Asthma
Idiopathic Pulmonary Fibrosis
Juvenile Idiopathic Arthritis
Lupus Nephritis
Multiple Sclerosis
Nasal Polyposis
Nonalcoholic Steatohepatitis (NASH)
Psoriasis
Psoriatic Arthritis
Rheumatoid Arthritis
Sickle Cell Disease
Sjogren’s Syndrome
Systemic Lupus Erythematosus
Systemic Sclerosis
Ulcerative Colitis

SMARTImmunology insights – Table of Contents:


  • Executive Summary Disease, Diagnosis, and Treatment

    • Overview and Risk Factors
    • Pathogenesis
    • Clinical Presentation and Diagnosis
    • Treatment Paradigm
    • Current Treatment Benchmarks
    • Residual Unmet Needs


  • Epidemiology

    • Prevalence – Current and Forecast (Major Markets)
    • Methodology and Sources


  • Emerging Treatment Landscape

    • Pipeline
    • Estimated Approval Timelines – US and EU
    • Promising Pipeline Drugs
    • Key Trial Failures
    • Discontinued Pipeline Assets


  • Regulatory Landscape

    • Regulatory Guidance and Precedence of Approval
    • Special Regulatory Status for Pipeline Assets
    • Clinical Trial Endpoints and Study Design


  • Target Opportunity Profile

    • Clinical Trial Considerations
    • Efficacy and Safety Thresholds – Minimal and Optimal


  • Pricing & Reimbursement

    • Pricing Benchmark
    • Summary of HTA Assessment of Key Drugs – UK, Germany and France


  • Appendix

    • Trial Profiles of Key Emerging Agents